Vernal Keratoconjunctivitis
Vernal Keratoconjunctivitis Market

Vernal Keratoconjunctivitis (VKC) is chronic allergic conjunctivitis, which is most often observed in young males. Although most allergic conjunctivitis types do not affect vision, VKC is not usual in damage to the cornea from the condition resulting in vision loss. Although it is typically seasonal, year-round symptoms can be seen, leading to uncertain diagnoses being made. It characteristically affects young males in hot, dry climates in a seasonal manner; however, this is not always the rule.

 

Vernal Keratoconjunctivitis is more prevalent in dry, hot climates, specifically in the Mediterranean Basin, the Middle East, Central, West Africa, India, and South America. It affects more frequently males than females. 


Vernal Keratoconjunctivitis Epidemiological Segmentation 

The Epidemiological Segmentation of Vernal Keratoconjunctivitis in total Market Market from 2017 to 2030 is segmented as:- 

  • Total Prevalent Population of Vernal Keratoconjunctivitis
  • Total Diagnosed Prevalent Cases of Vernal Keratoconjunctivitis
  • Gender-specific Diagnosed Prevalent Cases of Vernal Keratoconjunctivitis
  • Type-specific Diagnosed Prevalent Cases of Vernal Keratoconjunctivitis
  • Severity-specific Diagnosed Prevalent Cases of Vernal Keratoconjunctivitis
  • Age-specific Diagnosed Prevalent Cases of Vernal Keratoconjunctivitis


Vernal Keratoconjunctivitis Epidemiology 

  • The total prevalent population of Vernal Keratoconjunctivitis in the total market (7MM, China, Egypt, Saudi Arabia, and Russia) in 2017 was 4,752,356
  • The Prevalence of Vernal Keratoconjunctivitis in the United States in 2017 was 65,309
  • The diagnosed prevalence was higher for males as compared to females in all the total major markets countries


Vernal Keratoconjunctivitis Market

The market size of Vernal Keratoconjunctivitis (VKC) in total markets in 2017 was USD 307.89 million


Vernal Keratoconjunctivitis Market Drivers

  • The rise in the Prevalence
  • Disease awareness and diagnosis
  • Research and development


Vernal Keratoconjunctivitis Market Barriers

  • The weak emerging drug pipeline
  • Diagnostic Barriers
  • Limited approved therapies


Vernal Keratoconjunctivitis Emerging Drugs

The emerging drugs of the Vernal Keratoconjunctivitis market are 

  • Antolimab (AK002)
  • Bertilimumab/iCo-008
  • Nomacopan

And many others.  


Vernal Keratoconjunctivitis Key Players

The key players in the Vernal Keratoconjunctivitis market are

  • Allakos
  • iCo Therapeutics
  • Akari Therapeutics

And many others. 

Download Infographic